company background image
TLRY

TilrayNasdaqGS:TLRY Stock Report

Market Cap

US$5.4b

7D

11.3%

1Y

n/a

Updated

21 Oct, 2021

Data

Company Financials +
TLRY fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health3/6
Dividends0/6

TLRY Overview

Tilray, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products.

Tilray Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Tilray
Historical stock prices
Current Share PriceUS$11.56
52 Week HighUS$9.98
52 Week LowUS$23.04
Beta0
1 Month Change3.03%
3 Month Change-14.94%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-28.20%

Recent News & Updates

Oct 18

Is Tilray Stock Overvalued Or Undervalued? Still Overvalued Now, But Looking Cheap Enough

TLRY stock has now pulled back some 85% from early-year, bubbly highs. Shares aren't necessarily 'cheap' at this level, but valuation has come in. The longer-term strategy seems wise, and Tilray's reach and production capacity strongly suggest it can survive until the U.S. market finally opens up. The answer to a simple question suggests that TLRY has become one of the more attractive cannabis plays out there.

Oct 08
Tilray, Inc. (NASDAQ:TLRY) May be Risky for Institutions but Good for Traders

Tilray, Inc. (NASDAQ:TLRY) May be Risky for Institutions but Good for Traders

Tilray, Inc. (NASDAQ:TLRY), is far from the trading high at US$29 in February 2021 as the stock is currently searching for a bottom. The company has a gap in performance and a wide area of possible outcomes. The last earnings report has re-motivated some investors, and perhaps the company will indeed show meaningful growth, but until then, we will look at what the shareholder composition says about the company.

Oct 07

Tilray: Out Of Touch

Tilray reported another quarter consistent with the constant earnings misses of Canadian cannabis stocks. The company only reported minimal pro-forma growth above the FQ1'21 revenues of $165 million. The stock trades at nearly 10x FY22 sales targets, ex-distribution revenues, providing limited upside potential and substantial downside risk, if targets aren't met.

Sep 08

Tilray: 250 Million Reasons Shareholders Aren't Happy

Tilray continues to urge shareholders to approve Proposal 1 to lift the authorized share count to 990 million shares. The Canadian cannabis company has proposed a plan to boost FY24 (June) revenue to $4 billion while current analyst estimates are only $1.37 billion. Investors are rightfully balking at the company boosting the authorized shares by ~250 million when organic growth is preferred.

Aug 26
Estimating the Intrinsic Value of Tilray, Inc. (NASDAQ:TLRY)

Estimating the Intrinsic Value of Tilray, Inc. (NASDAQ:TLRY)

While cannabis remains one of the prominent growth stories, Tilray (NASDAQ:TLRY) is having one of the more peaceful periods in the history of this extremely volatile stock. Yet, after the latest declines, the stock could not make a fresh low, showing a sign of potential bottoming. In this article, we will examine the latest developments and examine the current intrinsic value based on the discounted cash flow (DCF) valuation model.

Shareholder Returns

TLRYUS PharmaceuticalsUS Market
7D11.3%2.1%2.6%
1Yn/a15.4%31.1%

Return vs Industry: Insufficient data to determine how TLRY performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how TLRY performed against the US Market.

Price Volatility

Is TLRY's price volatile compared to industry and market?
TLRY volatility
TLRY Beta0
Industry Beta0.65
Market Beta1

Stable Share Price: TLRY is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: Insufficient data to determine TLRY's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20182,100Irwin Simonhttps://www.tilray.com

Tilray, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products. The company operates through five segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, Wellness Business, and Business Under Development. It provides medical and adult-use cannabis products; pharmaceutical and wellness products; beverage alcohol products; and hemp-based food and other wellness products.

Tilray Fundamentals Summary

How do Tilray's earnings and revenue compare to its market cap?
TLRY fundamental statistics
Market CapUS$5.36b
Earnings (TTM)-US$374.73m
Revenue (TTM)US$563.62m

9.5x

P/S Ratio

-14.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TLRY income statement (TTM)
RevenueUS$563.62m
Cost of RevenueUS$424.43m
Gross ProfitUS$139.19m
ExpensesUS$513.92m
Earnings-US$374.73m

Last Reported Earnings

Aug 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.81
Gross Margin24.70%
Net Profit Margin-66.49%
Debt/Equity Ratio18.6%

How did TLRY perform over the long term?

See historical performance and comparison

Valuation

Is Tilray undervalued compared to its fair value and its price relative to the market?

13.1%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: TLRY ($11.56) is trading below our estimate of fair value ($13.31)

Significantly Below Fair Value: TLRY is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: TLRY is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: TLRY is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TLRY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TLRY is good value based on its PB Ratio (1.2x) compared to the US Pharmaceuticals industry average (3.1x).


Future Growth

How is Tilray forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?

58.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TLRY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: TLRY is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: TLRY's is expected to become profitable in the next 3 years.

Revenue vs Market: TLRY's revenue (22% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: TLRY's revenue (22% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TLRY's Return on Equity is forecast to be low in 3 years time (1.3%).


Past Performance

How has Tilray performed over the past 5 years?

-78.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TLRY is currently unprofitable.

Growing Profit Margin: TLRY is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TLRY is unprofitable, and losses have increased over the past 5 years at a rate of 78.2% per year.

Accelerating Growth: Unable to compare TLRY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TLRY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).


Return on Equity

High ROE: TLRY has a negative Return on Equity (-7.95%), as it is currently unprofitable.


Financial Health

How is Tilray's financial position?


Financial Position Analysis

Short Term Liabilities: TLRY's short term assets ($844.6M) exceed its short term liabilities ($526.8M).

Long Term Liabilities: TLRY's short term assets ($844.6M) do not cover its long term liabilities ($1.1B).


Debt to Equity History and Analysis

Debt Level: TLRY's debt to equity ratio (18.6%) is considered satisfactory.

Reducing Debt: TLRY's debt to equity ratio has increased from 10.6% to 18.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TLRY has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if TLRY has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Tilray current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TLRY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TLRY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TLRY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TLRY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TLRY's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Irwin Simon (63 yo)

2.58yrs

Tenure

US$13,683,999

Compensation

Mr. Irwin David Simon has been Chairman of the Board of Tilray, Inc. since December 27, 2018, Chief Executive Officer since March 1, 2019 and President since May 4, 2021. Mr. Simon has been Executive Chair...


CEO Compensation Analysis

Compensation vs Market: Irwin's total compensation ($USD13.68M) is above average for companies of similar size in the US market ($USD6.29M).

Compensation vs Earnings: Irwin's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: TLRY's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: TLRY's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 60.1%.


Top Shareholders

Company Information

Tilray, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Tilray, Inc.
  • Ticker: TLRY
  • Exchange: NasdaqGS
  • Founded: 2018
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$5.356b
  • Shares outstanding: 463.34m
  • Website: https://www.tilray.com

Number of Employees


Location

  • Tilray, Inc.
  • 655 Madison Avenue
  • Suite 1900
  • New York
  • New York
  • 10065
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/21 23:06
End of Day Share Price2021/10/21 00:00
Earnings2021/08/31
Annual Earnings2021/05/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.